186 related articles for article (PubMed ID: 22978745)
1. Anti-AIDS agents 90. novel C-28 modified bevirimat analogues as potent HIV maturation inhibitors.
Qian K; Bori ID; Chen CH; Huang L; Lee KH
J Med Chem; 2012 Sep; 55(18):8128-36. PubMed ID: 22978745
[TBL] [Abstract][Full Text] [Related]
2. Alkyl Amine Bevirimat Derivatives Are Potent and Broadly Active HIV-1 Maturation Inhibitors.
Urano E; Ablan SD; Mandt R; Pauly GT; Sigano DM; Schneider JP; Martin DE; Nitz TJ; Wild CT; Freed EO
Antimicrob Agents Chemother; 2016 Jan; 60(1):190-7. PubMed ID: 26482309
[TBL] [Abstract][Full Text] [Related]
3. Incorporation of Privileged Structures into Bevirimat Can Improve Activity against Wild-Type and Bevirimat-Resistant HIV-1.
Zhao Y; Gu Q; Morris-Natschke SL; Chen CH; Lee KH
J Med Chem; 2016 Oct; 59(19):9262-9268. PubMed ID: 27676157
[TBL] [Abstract][Full Text] [Related]
4. Anti-AIDS agents 81. Design, synthesis, and structure-activity relationship study of betulinic acid and moronic acid derivatives as potent HIV maturation inhibitors.
Qian K; Kuo RY; Chen CH; Huang L; Morris-Natschke SL; Lee KH
J Med Chem; 2010 Apr; 53(8):3133-41. PubMed ID: 20329730
[TBL] [Abstract][Full Text] [Related]
5. Anti-AIDS agents 73: structure-activity relationship study and asymmetric synthesis of 3-O-monomethylsuccinyl-betulinic acid derivatives.
Qian K; Nakagawa-Goto K; Yu D; Morris-Natschke SL; Nitz TJ; Kilgore N; Allaway GP; Lee KH
Bioorg Med Chem Lett; 2007 Dec; 17(23):6553-7. PubMed ID: 17935987
[TBL] [Abstract][Full Text] [Related]
6. Synthesis of betulinic acid derivatives as entry inhibitors against HIV-1 and bevirimat-resistant HIV-1 variants.
Dang Z; Qian K; Ho P; Zhu L; Lee KH; Huang L; Chen CH
Bioorg Med Chem Lett; 2012 Aug; 22(16):5190-4. PubMed ID: 22818973
[TBL] [Abstract][Full Text] [Related]
7. Synthesis and biological evaluation of a new derivative of bevirimat that targets the Gag CA-SP1 cleavage site.
Coric P; Turcaud S; Souquet F; Briant L; Gay B; Royer J; Chazal N; Bouaziz S
Eur J Med Chem; 2013 Apr; 62():453-65. PubMed ID: 23399723
[TBL] [Abstract][Full Text] [Related]
8. Discovery and synthesis of novel beesioside I derivatives with potent anti-HIV activity.
Wu H; Ma G; Yang Q; Zhu Y; Huang L; Tian Y; Yang X; Zhang M; Chen CH; Morris-Natschke SL; Yang M; Xu X; Lee KH
Eur J Med Chem; 2019 Mar; 166():159-166. PubMed ID: 30703659
[TBL] [Abstract][Full Text] [Related]
9. Fluorinated betulinic acid derivatives and evaluation of their anti-HIV activity.
Li J; Goto M; Yang X; Morris-Natschke SL; Huang L; Chen CH; Lee KH
Bioorg Med Chem Lett; 2016 Jan; 26(1):68-71. PubMed ID: 26598461
[TBL] [Abstract][Full Text] [Related]
10. Bifunctional anti-human immunodeficiency virus type 1 small molecules with two novel mechanisms of action.
Huang L; Yuan X; Aiken C; Chen CH
Antimicrob Agents Chemother; 2004 Feb; 48(2):663-5. PubMed ID: 14742233
[TBL] [Abstract][Full Text] [Related]
11. Betulinic acid derivatives as human immunodeficiency virus type 2 (HIV-2) inhibitors.
Dang Z; Lai W; Qian K; Ho P; Lee KH; Chen CH; Huang L
J Med Chem; 2009 Dec; 52(23):7887-91. PubMed ID: 19526990
[TBL] [Abstract][Full Text] [Related]
12. Synthesis and anti-HIV activity of 3-alkylamido-3-deoxy-betulinic acid derivatives.
Kashiwada Y; Chiyo J; Ikeshiro Y; Nagao T; Okabe H; Cosentino LM; Fowke K; Morris-Natschke SL; Lee KH
Chem Pharm Bull (Tokyo); 2000 Sep; 48(9):1387-90. PubMed ID: 10993248
[TBL] [Abstract][Full Text] [Related]
13. Triterpene derivatives that inhibit human immunodeficiency virus type 1 replication.
Dorr CR; Yemets S; Kolomitsyna O; Krasutsky P; Mansky LM
Bioorg Med Chem Lett; 2011 Jan; 21(1):542-5. PubMed ID: 21084190
[TBL] [Abstract][Full Text] [Related]
14. Anti-AIDS agents. 78. Design, synthesis, metabolic stability assessment, and antiviral evaluation of novel betulinic acid derivatives as potent anti-human immunodeficiency virus (HIV) agents.
Qian K; Yu D; Chen CH; Huang L; Morris-Natschke SL; Nitz TJ; Salzwedel K; Reddick M; Allaway GP; Lee KH
J Med Chem; 2009 May; 52(10):3248-58. PubMed ID: 19388685
[TBL] [Abstract][Full Text] [Related]
15. New betulinic acid derivatives for bevirimat-resistant human immunodeficiency virus type-1.
Dang Z; Ho P; Zhu L; Qian K; Lee KH; Huang L; Chen CH
J Med Chem; 2013 Mar; 56(5):2029-37. PubMed ID: 23379607
[TBL] [Abstract][Full Text] [Related]
16. Potent activity of the HIV-1 maturation inhibitor bevirimat in SCID-hu Thy/Liv mice.
Stoddart CA; Joshi P; Sloan B; Bare JC; Smith PC; Allaway GP; Wild CT; Martin DE
PLoS One; 2007 Nov; 2(11):e1251. PubMed ID: 18043758
[TBL] [Abstract][Full Text] [Related]
17. Synthesis and anti-HIV activity of bi-functional betulinic acid derivatives.
Huang L; Ho P; Lee KH; Chen CH
Bioorg Med Chem; 2006 Apr; 14(7):2279-89. PubMed ID: 16314103
[TBL] [Abstract][Full Text] [Related]
18. New Phosphorus Analogs of Bevirimat: Synthesis, Evaluation of Anti-HIV-1 Activity and Molecular Docking Study.
Chrobak E; Marciniec K; Dąbrowska A; Pęcak P; Bębenek E; Kadela-Tomanek M; Bak A; Jastrzębska M; Boryczka S
Int J Mol Sci; 2019 Oct; 20(20):. PubMed ID: 31640137
[TBL] [Abstract][Full Text] [Related]
19. Anti-AIDS agents. 34. Synthesis and structure-activity relationships of betulin derivatives as anti-HIV agents.
Sun IC; Wang HK; Kashiwada Y; Shen JK; Cosentino LM; Chen CH; Yang LM; Lee KH
J Med Chem; 1998 Nov; 41(23):4648-57. PubMed ID: 9804704
[TBL] [Abstract][Full Text] [Related]
20. Structure and Anti-HIV Activity of Betulinic Acid Analogues.
Huang QX; Chen HF; Luo XR; Zhang YX; Yao X; Zheng X
Curr Med Sci; 2018 Jun; 38(3):387-397. PubMed ID: 30074203
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
